{{'Search' | translate}}
 

Ethanol, Absolute (200 Proof), Molecular Biology Grade, Fisher BioReagentsTM

Company: Fisher Scientific
Catalog#: BP28184
Bio-protocol()
Company-protocol()
Other protocol()

Characterizing the Transcriptional Effects of Endolysin Treatment on Established Biofilms of Staphylococcus aureus
Author:
Date:
2018-06-20
[Abstract]  Biofilms are the most common lifestyle of bacteria in both natural and human environments. The organized structure of these multicellular communities generally protects bacterial cells from external challenges, thereby enhancing their ability to survive treatment with antibiotics or disinfectants. For this reason, the search for new antibiofilm strategies is an active field of study. In this context, bacteriophages (viruses that infect bacteria) and their derived proteins have been proposed as promising alternatives for eliminating biofilms. For instance, endolysins can degrade peptidoglycan and, ultimately, lyse the target bacterial cells. However, it is important to characterize the responses of bacterial cells exposed to these compounds in order to improve the design of phage-based ... [摘要]  生物膜是自然和人类环境中最常见的细菌生活方式。这些多细胞社区的有组织结构通常保护细菌细胞免受外部挑战,从而增强其抗生素或消毒剂治疗的生存能力。为此,寻找新的抗菌膜策略是一个积极的研究领域。在这种情况下,已提出噬菌体(感染细菌的病毒)及其衍生蛋白作为消除生物膜的有希望的替代物。例如,内溶素可降解肽聚糖,并最终裂解靶细菌细胞。然而,表征暴露于这些化合物的细菌细胞的反应以改进基于噬菌体的抗微生物策略的设计是重要的。

如以前在Fernández等人(2017)中所描述的,开发该协议以检查暴露于内溶素处理的金黄色葡萄球菌生物膜细胞的转录反应。然而,它可能随后适用于分析其他微生物对不同抗菌剂的反应。

【背景】越来越清楚的是,亚抑制剂量的抗菌剂可能对目标微生物的不同表型具有调节作用,包括生物膜形成,代谢或毒力。因此,研究新化合物对低浓度靶细胞的潜在影响应该是发展过程的一部分。事实上,引发毒力因子或抗生素耐药决定簇产生的非常有效的抗菌剂可能不是治疗应用的良好候选者。另一方面,考虑到生物膜和浮游细胞之间的生理差异,应该对生物膜形成细胞分析新抗生物膜剂的作用似乎是合乎逻辑的。在这里,我们描述了一种协议,用于分析生物膜细胞在亚抑制浓度的内抑素浓度下的转录反应,噬菌体来源的蛋白质作为生物膜去除剂展现出巨大的前景。因此,通过RNA-seq将内溶素处理的细胞的转录组与对照细胞进行比较,并且后来通过RT-qPCR证实了所选基因的差异表达。 ...

Advanced Design of Minimalistic Dumbbell-shaped Gene Expression Vectors
Author:
Date:
2017-08-05
[Abstract]  Minimal DNA vectors exclusively comprising therapeutically relevant sequences hold great promise for the development of novel therapeutic regimen. Dumbbell-shaped vectors represent non-viral non-integrating DNA minimal vectors which have entered an advanced stage of clinical development (Hardee et al., 2017). Spliceable introns and DNA nuclear import signals such as SV40 enhancer sequences are molecular features that have found multiple applications in plasmid vectors to improve transgene expression. In dumbbells however, effects triggered by introns were not investigated and DNA-based nuclear import sequences have not found applications yet, presumably because dumbbell vectors have continuously been minimized with regard to size. We investigated the effects of an intron and/or ... [摘要]  唯一包含治疗相关序列的最小DNA载体对于新型治疗方案的发展具有很大的希望。哑铃型载体代表已经进入临床发展的晚期阶段的非病毒非整合DNA最小载体(Hardee等人,2017)。可接合的内含子和DNA核输入信号如SV40增强子序列是在质粒载体中发现多个应用以改善转基因表达的分子特征。然而,在哑铃中,由内含子引发的效应未被研究,基于DNA的核导入序列尚未发现应用,可能是因为哑铃载体在尺寸上不断被最小化。我们调查内含子和/或SV40增强子衍生序列对哑铃载体驱动的报告基因表达的影响。发现可拼接内含子的实现在所有研究的细胞系中无条件地增强基因表达。相反,SV40增强子的使用改善了细胞类型依赖性的基因表达。虽然这两个特征显着增加哑铃载体大小,但内含子和增强子或两者的组合都不会对基因表达产生负面影响。相反,与质粒或对照哑铃相比,这两个特征在一起改善了哑铃驱动的基因表达,高达160-或56倍。因此,强烈建议考虑用于哑铃矢量设计的内含子和SV40增强子。这种先进的设计可以促进哑铃型DNA载体的临床前和临床应用。
【背景】虽然许多基因已经使用哑铃形DNA载体表达,但大多数这些应用使用包括启动子,编码序列(CDS)和转录终止子的基本设计。一些载体包括嵌合内含子,然而,没有报道通过这种设计增强了转基因表达(Schirmbeck等人,2001)。在这里,我们研究了分子特征引发的效应,这些特征经常在哑铃驱动基因表达的质粒设计中得到应用:1.已知来自人β-珠蛋白基因剪接的嵌合内含子促进RNA加工,核出口,随后基因表达(Luo ...

Formation of Minimised Hairpin Template-transcribing Dumbbell Vectors for Small RNA Expression
Author:
Date:
2017-06-05
[Abstract]  A major barrier for using non-viral vectors for gene therapy is the short duration of transgene expression in postmitotic tissues. Previous studies showed transgene expression from conventional plasmid fell to sub-therapeutic level shortly after delivery even though the vector DNA was retained, suggesting transcription was silenced in vivo (Nicol et al., 2002; Chen et al., 2004). Emerging evidence indicates that plasmid bacterial backbone sequences are responsible for the transcriptional repression and this process is independent of CpG methylation (Chen et al., 2008). Dumbbell-shaped DNA vectors consisting solely of essential elements for transgene expression have been developed to circumvent these drawbacks. This novel non-viral vector has been shown ... [摘要]  使用非病毒载体进行基因治疗的主要障碍是在postmitotic组织中转基因表达的持续时间短。以前的研究表明,即使载体DNA被保留,传代质粒的转基因表达也在递送后不久就下降到亚治疗水平,提示转录在体内沉默(Nicol等人)。 ,2002; Chen等人,2004)。新出现的证据表明质粒细菌骨架序列负责转录抑制,该过程与CpG甲基化无关(Chen等人,2008)。仅开发了用于转基因表达的必需元件的哑铃型DNA载体已被开发出来,以规避这些缺点。已经显示这种新的非病毒载体在体外和体内改善转基因表达(Schakowski等人,2001和2007)。在这里我们描述一种快速有效地生产最小化的表达小RNA的哑铃载体的新方法。简言之,将PCR扩增的启动子序列连接到化学合成的发夹RNA编码DNA模板以形成共价闭合的哑铃载体。这种新技术可以促进哑铃型载体用于临床前研究和人类基因治疗的应用。

背景 关于递送,小的载体大小有利地改善细胞外转运,包括通过细胞外基质网络的外渗和扩散以及细胞摄取和核扩散。已经开发了各种哑铃载体生产方法,包括产生表达小RNA的哑铃的方法,例如小发夹RNA(shRNA)和微小RNA(miRNA)(Schakowski等人,2001; ...

Comments